MANE Veradermics, Incorporated
Company Analysis
Latest News
🔴 Veradermics falls 4.1% — Biotech Sector Cools Off After Moderna-Sparked Rally
With Biotech (XBI) down 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a pullback after a...
🔴 Veradermics is trading 4.6% down today after no clear company-specific catalyst emerged
Veradermics is trading 4.6% down now at $107.55 (-4.58%) after no clear August 17, 2026 company-specific catalyst emerged. - The latest company announcement...
Veradermics second quarter 2026 cash reserves of $820M significantly exceed estimates following capital raises
Veradermics reported a second quarter 2026 net loss of $23.5 million on zero revenue, as the company continues to focus on its clinical pipeline for pattern...
🔴 Veradermics is trading 4.52% down today after potential sale of 16.77 million shares
Veradermics is trading 4.52% down now at $109.22 as investors weigh potential share supply from recently unlocked holdings. - A filing disclosed certain...
Veradermics, Incorporated Q2 2026 Earnings Preview: What Analysts Expect on August 11, 2026
Veradermics, Incorporated is expected to report zero revenue and a consensus EPS loss of -$0.63 for Q2 2026, with the stock currently trading at $114.39...
🟢 Veradermics is trading 4.4% up today on broader biotech sector strength
Veradermics is trading 4.4% up at $111.95 today, tracking a broader upswing across the biotechnology sector rather than stock-specific news. • The move...
🟢 Veradermics is trading 4.6% up today on a rebound amid a broader biotech rally
Veradermics is trading 4.6% up today at $106.58 as the stock rebounds from recent post-IPO volatility and participates in a strong risk-on rally across biotech...
🔴 Veradermics is trading 4.5% down today amid post-IPO volatility following a strong July run-up
Veradermics is trading 4.5% down at $101.07 amid ongoing volatility following its recent NYSE listing and a significant price surge throughout July. • The...
🟢 Veradermics is trading 4.1% up today on follow-through from recent strength
Veradermics is trading 4.1% up at $115.95, extending a volatile pattern seen over the past week characterized by multiple ±5% swings. • There is no fresh...
🟢 Veradermics rises 4.4% — Biotech Sector Rallies on Blockbuster M&A Deal and Positive Trial Data
With Biotech (XBI) up 2.3%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Veradermics is trading 4.4% down today on profit-taking after recent multi-session gains
Veradermics is trading 4.4% down at $110.78 as the stock pulls back following a sharp multi-session advance. • The decline follows significant recent...
🟢 Veradermics is trading 5.1% up
Veradermics is trading at $115.45, up 5.1% from a comparison close of $109.85 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 Veradermics Jumps 4.1% After Positive Female Hair Loss Trial Results
Veradermics is trading at $110.42 (4.13% up) today. • The surge follows positive topline results from its Phase 2 clinical trial (Study '207') of VDPHL01 in...
🔴 Veradermics is trading 4.1% down today in a pullback after recent volatility
Veradermics is trading at $106.75, down 4.1%, in an apparent pullback following a week of sharp gains and losses. • The move occurs in the absence of fresh...
🟢 Veradermics is trading 10.2% up
Veradermics is trading at $116.66, up 10.2% from a comparison close of $105.83 during regular trading. This is a price-action follow-up, so a separate catalyst...
🟢 Veradermics is trading 4.54% up today, rebounding after a sharp prior-day drop
Veradermics is trading 4.54% up at $110.63 as the stock attempts to recover from a sharp decline during the previous trading session. • No company-specific...
🔴 Veradermics is trading 10.6% down
Veradermics is trading at $110.55, down 10.6% from a comparison close of $123.70 during regular trading. This is a price-action follow-up, so a separate...
🔴 Veradermics is trading 5% down today as investors digest gains from positive Phase 2 trial results
Veradermics is trading at $117.48 (5% down) as the stock gives back a portion of yesterday's gains following a sharp rally triggered by positive Phase 2 trial...
Veradermics Reports Positive Phase 2 Trial Results for Hair Loss Drug VDPHL01 in Females
Veradermics, Inc. (MANE) announced positive topline results from its Phase 2 clinical trial, Study ‘207,’ for its investigational oral hair loss treatment,...
🟢 Veradermics is trading 13.5% up
Veradermics is trading at $125.09, up 13.5% from a comparison close of $110.17 during regular trading. This is a price-action follow-up, so a separate catalyst...